# IAP7 Rec'd PCT/PTO 13 JAN 2006

PCT

Atty. Dkt. No. 064189-0604



### E UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Heinz-Josef LENZ, et al.

Title:

POLYMORPHISMS FOR PREDICTING DISEASE AND

TREATMENT OUTCOME

Appl. No.:

10/522,664

Filing Date:


July 31, 2003

Examiner:

Unassigned

Art Unit:

Unassigned



## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *primâ facile* art reference against the claims of the present application.

SVCA\_28311.1

-1-

any document which is determined to be a *prima facie* art reference against the claims of the present application.

### TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, and within three (3) months of the mailing date of the foreign search report.

### RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Applicants also bring to the Office's attention the following related applications: U.S. Patent Application Serial Nos.: 11/173,889, filed July 1, 2005 and 09/715,764, filed November 15, 2005.

The Commissioner is hereby authorized to charge any fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872.

Respectfully submitted,

Date: January 11, 2006

FOLEY & LARDNER LLP Customer Number: 38706 Telephone: (650) 251-1129 Facsimile: (650) 856-3710 Antoinette F. Konski Attorney for Applicant Registration No. 34,202 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for for	m 1449B/	PTO		Complete if Known		
	INFORMATION	DISCLO	SURE	Application Number	10/522,664		
	STATEMENT BY	Y APPLI	CANT	Filing Date	July 31, 2003		
	Data Culturalitado I		1 2006	First Named Inventor	Heinz-Josef Lenz		
	Date Submitted: J	anuary i	1, 2006	Group Art Unit	Not Yet Assigned		
	(use as many shee	ts as ne	cessary)	Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	064189-0604		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	1	6,716,581	B1	Lenz et al.	4/6/04	
•						
·						
					•	

	U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Cito	U.S. Patent Ap		Name of Patentee or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant
		Serial Number	Kind Code <sup>2</sup> (if known)	Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
	2	2004/0067519	A1	Lenz	08/05/03		
				- Physician			
	<b>_</b>						
			-				
			· · · · · · · · ·				

		<del></del>
Examiner	Date Considered	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form	1449B/	PTO	Complete if Known		
	INFORMATION D	ISCLO	SURE	Application Number	10/522,664	_
	STATEMENT BY	APPLI	CANT .	Filing Date	July 31, 2003	
	Data Cubmittad: Jan	nuoni 1	1 2006	First Named Inventor	Heinz-Josef Lenz	
	Date Submitted: Jar	nuary i	1, 2006	Group Art Unit	Not Yet Assigned	
	(use as many sheets	s as ne	cessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	064189-0604	

_	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent D		ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>		
	3	WO	04/037852	A2	University of Medicine and Dentistry of New Jersey; University of Southern California	May 6, 2004				
					·					

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	4	IACOPETTA, B. et al. "A Polymorphism in the Enhancer Region of the Thymidylate Synthase Promoter Influences the Survival of Colorectal Cancer Patients Treated with 5-Fluorouracil" <i>British Journal of Cancer, London, GB</i> " (September 14, 2001) 85(6):827-830	
	5	LENZ, HEINZ-JOSEF et al. "A 6 base-pair deletion in the 3 UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors: A possible candidate gene for colorectal cancer risk" Proceedings of the American Association for Cancer Research Annual Meeting (March 2002) 43:660	
	6	PARK, DAVID J. et al. "Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer" <i>International Journal of Colorectal Disease</i> (January 2002) 17(1):46-49	
	7	PULLARKAT, S. et al. "Thymidylate Synthase Gene Polymorphism Determines Response and Toxicity of 5-FU Chemotherapy" <i>Pharmacogenomics Journal</i> (2001) 1(1):65-70	
***	8	SHIROTA, Y. et al. "ERCC1 and Thymidylate Synthase MRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy" <i>Journal of clinical Oncology</i> (December 1, 2001) 19(23):4298-4304	
	9	Ulrich et al. "Searching Expressed Sequence Tag Databases: Discovery and Confirmation of a Common Polymorphism in the <i>Thymidylate Synthase</i> Gene" <i>Cancer Epidemiology, Biomarkers &amp; Prevention</i> (2000) 9:1381-1385	
	10	Villafranca et al. "Polymorphisms of the Repeated sequences in the Enhancer Region of the Thymidylate Synthase Gene Promoter May Predict Downstaging After Preoperative Chemoradiation in Rectal Cancer" (2001) Journal of Clinical Oncology 19(6):1779-1786	
	11	European Search Report for EP 03 77 2163 dated October 4, 2005	

Examiner Signature	Date Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language